SAN DIEGO and SOUTH SAN FRANCISCO, Calif., Feb. 3 /PRNewswire/ -- Fluidigm Corporation and Syrrx, Inc. today announced that Fluidigm has obtained from Syrrx license rights directed to the submicroliter crystallization of proteins. The terms of the agreement were not disclosed.
Through its exclusive license with Lawrence Berkeley National Laboratory, Syrrx obtained broad patent protection for the crystallization of proteins in submicroliter volumes. Fluidigm's non-exclusive license with Syrrx provides it with freedom to operate relative to this significant family of patents. Fluidigm acquired the license to support the commercialization of Fluidigm's Topaz(TM) system for protein crystallization. The Topaz(TM) system addresses the entire process from the setup of crystallization experiments to the diffraction of crystals and is based on proprietary Topaz chips, which consume nanogram quantities of protein per trial. Leading pharmaceutical companies and academic institutions use the system to elucidate the three-dimensional structure of protein drug targets, providing extremely valuable information in the design of blockbuster drugs.
"The Topaz system is fast emerging as a standard in the structural biology laboratory because of its ability to quickly generate crystals for elucidating the structure of proteins," said Fluidigm CEO Gajus Worthington. "This is critical as experts estimate a 50% cost and time savings when protein structure is used as a central part of the drug discovery process."
"Syrrx has worked diligently to develop a significant patent position around the submicroliter crystallization of proteins," added David J. Weitz, Syrrx General Counsel. "We are excited to see Fluidigm commercialize submicroliter crystallization and become Syrrx' first system manufacturer licensee. Syrrx looks forward to securing other licensees as submicroliter crystallization is more widely adopted."
About Syrrx, Inc.
Syrrx, Inc. (http://www.syrrx.com/) is a drug discovery company, based in San Diego, California, with a focus on drug targets that have been validated in human clinical trials. Syrrx exploits its competitive advantage in high-throughput structural biology to be the first organization to determine the three dimensional structure of known drug targets. Syrrx then uses these structures to drive an iterative, structure-based drug design program to efficiently generate potential drug candidates. Syrrx directs its efforts toward therapeutics to treat cancer, metabolic diseases and inflammation.
Fluidigm Corporation develops and manufactures complete systems, enabled by the integrated fluidic circuit, that revolutionize life-science research. Fluidigm's initial customer base is in the drug discovery and life sciences arena; initial products address the challenges of protein structure determination. Based in South San Francisco, California, Fluidigm is privately held and backed by premier investors, including Versant Ventures, Euclid SR Partners, InterWest Partners, Lehman Brothers Healthcare Fund, Bruce Burrows,
the Singapore EDB, Lilly BioVentures, the Invus Group, GE Equity, and Piper Jaffray Ventures.
For more information about the Topaz system, visit http://www.fluidigm.com/.
Fluidigm Corporation; Syrrx, Inc.
CONTACT: media, Jaime Bartels, Public Relations Manager of FluidigmCorporation, +1-650-266-6014, or email@example.com; or media, Keith.P. Wilson, Vice President, Bus. Dev., +858-731-3684, firstname.lastname@example.org, or investors, Jean Lockhart, Vice President, Finance,+858-731-3512, or email@example.com, both of Syrrx, Inc.